Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes

作者：Liu, Si-Yang; Bao, Hua; Wang, Qun; Mao, Wei-Min; Chen, Yedan; Tong, Xiaoling; Xu, Song-Tao; Wu, Lin; Wei, Yu-Cheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Sheng-Xiang; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yan, Hong-Hong; Dong, Song; Zhang, Xu-Chao; Su, Jian; Yang, Jin-Ji; Yang, Xue-Ning; Zhou, Qing; Wu, Xue; Shao, Yang; Zhong, Wen-Zhao^*

来源：Nature Communications, 2021, 12(1): 6450.

DOI：10.1038/s41467-021-26806-7

• VINORELBINE PLUS CISPLATIN
• GENETIC ALTERATIONS
• POOLED ANALYSIS
• TP53 MUTATIONS
• NSCLC PATIENTS
• SURVIVAL
• PLACEBO
• TRIALS
• RESISTANCE
• CARCINOMAS

The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II-IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI), raising the necessity for further biomarker assessment. In this work, by comprehensive genomic profiling of 171 tumor tissues from the ADJUVANT trial, five predictive biomarkers are identified (TP53 exon4/5 mutations, RB1 alterations, and copy number gains of NKX2-1, CDK4, and MYC). Then we integrate them into the Multiple-gene INdex to Evaluate the Relative benefit of Various Adjuvant therapies (MINERVA) score, which categorizes patients into three subgroups with relative disease-free survival and overall survival benefits from either adjuvant gefitinib or chemotherapy (Highly TKI-Preferable, TKI-Preferable, and Chemotherapy-Preferable groups). This study demonstrates that predictive genomic signatures could potentially stratify resected EGFR-mutant NSCLC patients and provide precise guidance towards future personalized adjuvant therapy. @@@ Adjuvant gefitinib improves outcomes in non-small cell lung cancer (NSCLC) patients compared to chemotherapy, but not in all cases. Here, the authors find genomic biomarkers of response to gefitinib in NSCLC patients from the ADJUVANT trial, and propose a score to stratify them by potential benefit from the treatment.

• 单位
  青岛大学; 复旦大学; 中国医科大学; 哈尔滨医科大学; 北京大学; 四川大学; 1; 广东省人民医院